CytomX shifts towards EpCAM

Published on January 7, 2025

CytomX has struggled to convince investors of the merits of its conditionally acting anti-EGFR T-cell engaging probody CX-904, and this

Continue reading on website
Other news

Decarbon8-US Impact Fund Drives Investment of Over $800,000 into Three Renewable Energy Startups

January 7, 2025
of investment into three companies chosen for the philanthropic fund, Decarbon8-US 2024, through both philanthropic and direct investment.

Water.org Builds on FY24 Progress to Solve the Global Water Crisis

January 7, 2025
the capital markets, the bond mobilizes resources from institutional investors to provide the people in these regions with the capital they